Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02158936
Registration number
NCT02158936
Ethics application status
Date submitted
5/06/2014
Date registered
9/06/2014
Date last updated
12/12/2017
Titles & IDs
Public title
A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)
Query!
Scientific title
A Randomized, Double-blind, Placebo-controlled, Phase III, Multi-centre Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With IPSS Intermediate-1, Intermediate 2 and High-risk Myelodysplastic Syndromes (MDS) SUPPORT: A StUdy of eltromboPag in myelodysPlastic SyndrOmes Receiving azaciTidine
Query!
Secondary ID [1]
0
0
112121
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Thrombocytopaenia
0
0
Query!
Condition category
Condition code
Blood
0
0
0
0
Query!
Haematological diseases
Query!
Blood
0
0
0
0
Query!
Other blood disorders
Query!
Other
0
0
0
0
Query!
Research that is not of generic health relevance and not applicable to specific health categories listed above
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Eltrombopag
Treatment: Drugs - Azacitidine
Treatment: Drugs - Placebo
Treatment: Drugs - Placebo
Experimental: Eltrombopag - Eligible subject will receive a starting dose of eltrombopag of 200 milligrams (mg) (100 mg for subjects of East Asian heritage). Dose modifications of eltrombopag will be permitted by 100 mg increments (50 mg increments for East Asians) to a lowest dose of 100 mg (50 mg for East Asian heritage) or a maximum dose of 300 mg (150 mg for East Asian heritage) in order to maintain platelet counts at a safe and effective level (i.e. a level sufficient to avoid platelet transfusions and bleeding events). Subjects will receive azacitidine 75 mg/meter\^2 subcutaneously once daily for 7 days (+/- 3 day treatment window permitted) every 28 days, for at least 6 cycles if tolerated and until they are no longer receiving benefit (defined as at least stable disease per the investigator's assessment) or until disease progression, death, or unacceptable toxicity/adverse event. The subject may receive eltrombopag daily for the full 28 days each cycle for as long as the subject is receiving azacitidine
Placebo comparator: Placebo - Eligible subject will receive eltrombopag matching placebo. Subjects will receive azacitidine 75 mg/meter\^2 subcutaneously once daily for 7 days (+/- 3 day treatment window permitted) every 28 days, for at least 6 cycles if tolerated and until they are no longer receiving benefit (defined as at least stable disease per the investigator's assessment) or until disease progression, death, or unacceptable toxicity/adverse event. The subject may receive eltrombopag daily for the full 28 days each cycle for as long as the subject is receiving azacitidine
Treatment: Drugs: Eltrombopag
Eltrombopag will be round film-coated tablets containing eltrombopag equivalent to 50 mg (white to off-white), 200 mg and 300 mg (green) of eltrombopag free acid
Treatment: Drugs: Azacitidine
Subcutaneous Injection (IV if local standard)
Treatment: Drugs: Placebo
Eltrombopag matching placebo tablets
Treatment: Drugs: Placebo
Eltrombopag matching placebo tablets will be supplied
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants Who Were Platelet Transfusion Independent During Cycles 1-4 of Azacitidine Therapy
Query!
Assessment method [1]
0
0
A subject is defined as being platelet transfusion independent if they received no platelet transfusions within the first 4 cycles of treatment with azacitidine. Subjects who died or withdrew from investigational product within the first four cycles were treated as failures (i.e. not transfusion independent) in the analysis
Query!
Timepoint [1]
0
0
4 cycles (Cycle = 28 days)
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
Overall survival is defined as the time from randomization until death due to any cause and deaths have been presented. Subjects still alive at the time of the analysis and subjects who have withdrawn from the study will be censored at the time of last contact
Query!
Timepoint [1]
0
0
Randomization until death or end of study, approximately 2 years
Query!
Secondary outcome [2]
0
0
Summary of Progression Free Survival From Investigator Assessment (ITT)
Query!
Assessment method [2]
0
0
Progression-free survival, defined as the time from randomization until either disease progression or death. The modified 2006 IWG criteria for MDS used for progression assessment For patients with: Less than 5% BM blasts: = 50% increase in blasts to \> 5% blasts; 5% - \<10% BM blasts: = 50% increase to \> 10% blasts; 10% - \<20% BM blasts: = 50% increase to \> 20% blasts; 20% - 30% BM blasts: = 50% increase to \> 30% blasts
Query!
Timepoint [2]
0
0
First day of each cycle (Cycles 3+), at the end of therapy visit and every 3 months in follow-up for approximately 2 years
Query!
Secondary outcome [3]
0
0
Summary of Progression Free Survival From Central Review (ITT)
Query!
Assessment method [3]
0
0
Progression-free survival, defined as the time from randomization until either disease progression or death. The modified 2006 IWG criteria for MDS used for progression assessment For patients with:
Less than 5% BM blasts: = 50% increase in blasts to \> 5% blasts; 5% - \<10% BM blasts: = 50% increase to \> 10% blasts; 10% - \<20% BM blasts: = 50% increase to \> 20% blasts; 20% - 30% BM blasts: = 50% increase to \> 30% blasts
Query!
Timepoint [3]
0
0
First day of each cycle (Cycles 3+), at the end of therapy visit and every 3 months in follow-up for approximately 2 years
Query!
Secondary outcome [4]
0
0
Summary of AML Progression From Investigator Assessment and Central Review (ITT)
Query!
Assessment method [4]
0
0
Progression to AML in MDS patients with baseline bone marrow blast \< 20% was defined as meeting definition of disease progression according to the modified 2006 IWG response criteria for MDS with the additional requirement that bone marrow blast or peripheral blast increases from \< 20% at baseline to = 20% postbaseline. Progression assessment For patients with:
Less than 5% BM blasts: = 50% increase in blasts to \> 5% blasts; 5% - \<10% BM blasts: = 50% increase to \> 10% blasts; 10% - \<20% BM blasts: = 50% increase to \> 20% blasts; 20% - 30% BM blasts: = 50% increase to \> 30% blasts
Query!
Timepoint [4]
0
0
First day of each cycle (Cycles 3+), at the end of therapy visit and every 3 months in follow-up for approximately 2 years
Query!
Secondary outcome [5]
0
0
Best Disease Response From Investigator Assessment (ITT)
Query!
Assessment method [5]
0
0
Best disease response is categorized as complete remission (CR), partial remission (PR), or marrow CR, stable disease, disease progression, or as non-evaluable; according to modified 2006 International Working Group (IWG) criteria for MDS
Query!
Timepoint [5]
0
0
At end of Cycle 6 (cycle=28 days) or end of therapy, whichever came first
Query!
Secondary outcome [6]
0
0
Best Disease Response From Central Review (ITT)
Query!
Assessment method [6]
0
0
Best disease response is categorized as complete remission (CR), partial remission (PR), or marrow CR, stable disease, disease progression, or as non-evaluable; according to modified 2006 International Working Group (IWG) criteria for MDS
Query!
Timepoint [6]
0
0
At end of Cycle 6 (cycle=28 days) or end of therapy, whichever came first
Query!
Secondary outcome [7]
0
0
Hematologic Improvement (HI) in Platelets, Neutrophils, and Hemoglobin Based on the Modified IWG Criteria for MDS (ITT)
Query!
Assessment method [7]
0
0
HI based on the modified IWG criteria for MDS. HI - Platelets (BL \<100Gi/L), response criteria= BL \<20: increase to\>20 and 100% at least for 56 days or BL \>=20: absolute increase of \>=30. HI - Neutrophils (BL \<1.0 Gi/L), response criteria=100% increase and an absolute increase \>0.5 Gi/L over BL for at least 56 days. HI-Hemoglobin (BL \<g/dL), response criteria=Hgb increase by \>=1.5 g/dL over BL, RBC transfusions(given for Hgb\<=9.0) reduced by \>=4 per 8w from BL
Query!
Timepoint [7]
0
0
From Day 1 to 4-week follow-up (samples collected weekly in Cycle 1, Days 1 and 15 in Cycles 2-6 and Day 1 of Cycles >=7)
Query!
Secondary outcome [8]
0
0
Number of Participants Who Were Platelet Transfusion Independent (ITT Set)
Query!
Assessment method [8]
0
0
Platelet transfusion independence is defined for each cycle as the number of participants who continue to the end of a cycle without requiring a platelet transfusion
Query!
Timepoint [8]
0
0
From Day 1 to end of study treatment up to approximately 2 years
Query!
Secondary outcome [9]
0
0
Bleeding Adverse Events (AEs) >= Grade 3
Query!
Assessment method [9]
0
0
Bleeding will be assessed by recording AEs or serious adverse events (SAEs) as graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Query!
Timepoint [9]
0
0
From Day 1 to 4-week follow-up up to approximately 2 years
Query!
Secondary outcome [10]
0
0
Number of of Subjects With Azacitidine Dose Delays, Dose Reductions, Interruptions
Query!
Assessment method [10]
0
0
The proportion of subjects with any delay, reduction or interruption in dosage of Azacitidine excluding those for non-medical reasons will be analyzed
Query!
Timepoint [10]
0
0
From Day 1 to 4-week follow-up up to approximately 2 years
Query!
Secondary outcome [11]
0
0
Response Levels in All Domains of Euroquol-5 Dimensions of Health, 3 Response Levels (EQ-5D-3L™)
Query!
Assessment method [11]
0
0
The EQ-5D is a general health status and health utility measure which captures 5 dimensions of health state: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. (EQ-5D is a trademark of the Stichting EuroQol Group) . C=cycle, D=Day
Query!
Timepoint [11]
0
0
From Day 1 to 4-week follow-up up to approximately 2 years
Query!
Secondary outcome [12]
0
0
Functional Assessment of Chronic Disease Therapy-fatigue Subscale (FACIT-Fatigue) (ITT)
Query!
Assessment method [12]
0
0
The FACIT-Fatigue subscale measures severity and impact of fatigue on functioning and Health Related QoL experienced in the past 7 days. Scale is a 13 item measure of fatigure. Items are scored on a 0-4 response scale ranging from "not at all" to "very much so". All items are summed to create a single fatigure score with a range from 0 to 52. Items are reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatiigue (The FACIT Fatigue Scale is owned by David Cella, Ph.D.)
Query!
Timepoint [12]
0
0
From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years
Query!
Secondary outcome [13]
0
0
Medical Resource Utilization (MRU): Event -Hospitalizations Inpatient and Outpatient
Query!
Assessment method [13]
0
0
MRU data will be collected for each subject. Events corresponding to unscheduled (not scheduled per protocol) hospitalizations
Query!
Timepoint [13]
0
0
From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years
Query!
Secondary outcome [14]
0
0
Medical Resource Utilization (MRU): Event and Use of Site Specific Medical Resources - Non-study Laboratory Tests
Query!
Assessment method [14]
0
0
MRU data will be collected for each subject. Events corresponding to unscheduled (not scheduled per protocol) hospitalizations, office visits including consultations, laboratory and diagnostic tests (lab results, imaging etc.), and procedures prior to therapy initiation and during therapy will be collected
Query!
Timepoint [14]
0
0
From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years
Query!
Secondary outcome [15]
0
0
Medical Resource Utilization (MRU): Use of Site Specific Medical Resources
Query!
Assessment method [15]
0
0
MRU data will be collected for each subject. Events corresponding to unscheduled (not scheduled per protocol) hospitalizations, office visits including consultations, laboratory and diagnostic tests (lab results, imaging etc.), and procedures prior to therapy initiation and during therapy will be collected
Query!
Timepoint [15]
0
0
From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years
Query!
Secondary outcome [16]
0
0
Summary of Post-Hoc Estimates of Steady-state Eltrombopag Cmax and Cmin Pharmacokinetic Parameters for a 50 mg Dose
Query!
Assessment method [16]
0
0
Eltrombopag concentrations were analyzed using a population PK model along with data from other studies in healthy volunteers and in patients with MDS and/or AML. Post-hoc PK parameters were derived. Only patients from this study were included (163)
Query!
Timepoint [16]
0
0
Cycle 1, Week 2: Pre-dose, 1.5 and 3 hour post dose; Cycle 1, Week 3: 4, 5.5, and 7 hours post dose
Query!
Secondary outcome [17]
0
0
Summary of Post-Hoc Estimates of Steady-state Eltrombopag AUC0 Infinity Pharmacokinetic Parameters for a 50 mg Dose
Query!
Assessment method [17]
0
0
Eltrombopag concentrations were analyzed using a population PK model along with data from other studies in healthy volunteers and in patients with MDS and/or AML. Post-hoc PK parameters were derived. Only patients from this study were included (163)
Query!
Timepoint [17]
0
0
Cycle 1, Week 2: Pre-dose, 1.5 and 3 hour post dose; Cycle 1, Week 3: 4, 5.5, and 7 hours post dose
Query!
Secondary outcome [18]
0
0
AUC0-infinity -Pharmacokinetic(s) Parameter of Azacitidine
Query!
Assessment method [18]
0
0
An analysis of variance (ANOVA) on AUC0-infinity. The PK parameters were log transformed prior to analysis. The model included treatment as a fixed effect. Point estimates and their associated 90% CI were constructed for the differences in PK parameter values. The point estimates and their associated 90% CI were then back transformed to provide point estimates and 90% CI for the azacitidine + eltrombopag:azacitidine + placebo PK parameter ratios.
Query!
Timepoint [18]
0
0
Cycle 2 Day 1: Pre-dose, 15 min, 0.5, 1, 2 and 4 hr post dose
Query!
Secondary outcome [19]
0
0
Cmax -Pharmacokinetic Parameter of Azacitidine
Query!
Assessment method [19]
0
0
An analysis of variance (ANOVA) on Cmax . The PK parameters were log transformed prior to analysis. The model included treatment as a fixed effect. Point estimates and their associated 90% CI were constructed for the differences in PK parameter values. The point estimates and their associated 90% CI were then back transformed to provide point estimates and 90% CI for the azacitidine + ltrombopag:azacitidine + placebo PK parameter ratios.
Query!
Timepoint [19]
0
0
Cycle 2 Day 1: Pre-dose, 15 min, 0.5, 1, 2 and 4 hr post dose
Query!
Eligibility
Key inclusion criteria
* Age >=18 years (For subjects in Taiwan, Age >= 20 years)
* MDS by World Health Organization (WHO) or French-American-British (FAB) classification
* Intermediate 1, intermediate 2 or high risk MDS by IPSS
* At least one platelet count < 75 Gi/L
* Eastern Cooperative Oncology Group (ECOG) Status 0-2
* Adequate baseline organ function defined by the criteria below: total bilirubin =< 1.5x the upper limit of normal (ULN) except for Gilbert's syndrome or cases clearly not indicative of inadequate liver function (i.e. elevation of indirect [haemolytic] bilirubin in the absence of alanine aminotransferase [ALT] abnormality); ALT =< 2.5xULN; creatinine =< 2.5xULN
* Subjects with a corrected QT interval (QTc) <450 milliseconds (msec) or <480msec for subjects with bundle branch block. The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF), machine or manual overread. For subject eligibility and withdrawal, QTcF will be used. For purposes of data analysis, QTcF will be used. The QTc should be based on single or averaged QTc values of triplicate electrocardiograms (ECGs) obtained over a brief recording period
* Subject is able to understand and comply with protocol requirements and instructions
* Subject has signed and dated informed consent
* Women must be either of non-child bearing potential, or women with child-bearing potential and men with reproductive potential must be willing to practice acceptable methods of birth control during the study
* Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of first dose of study treatment and agree to use effective contraception during the study and for 3 months following the last dose of study treatment
* Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from time of randomization until 16 weeks after the last dose of study treatment
* French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Previous treatment with hypomethylating agent or induction chemotherapy for MDS
* Proliferative type chronic myelomonocytic leukemia with white blood cell count >12 Gi/L at any time during the 28 days before Day 1
* History of treatment with eltrombopag, romiplostim or other thrombopoietin receptor (TPO-R) agonists
* Previous allogeneic stem-cell transplantation
* Known thrombophilic risk factors. Exception: Subjects for whom the potential benefits of participating in the study outweigh the potential risks of thromboembolic events, as determined by the investigator
* Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of investigational product (eltrombopag/placebo)
* Active and uncontrolled infections, including hepatitis B or C
* Human Immunodeficiency Virus (HIV) infection
* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to eltrombopag or its excipient, or azacitidine, that contraindicates the subjects' participation
* Pregnant or lactating female
* Any serious and/or unstable pre-existing medical condition (including any advanced malignancy other than the disease under study), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance with the study procedures
* French subjects: the French subject has participated in any study using an investigational drug during the previous 30 days
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
10/06/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
30/04/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
356
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - Kogarah
Query!
Recruitment hospital [2]
0
0
Novartis Investigative Site - Adelaide
Query!
Recruitment hospital [3]
0
0
Novartis Investigative Site - Clayton
Query!
Recruitment hospital [4]
0
0
Novartis Investigative Site - East Melbourne
Query!
Recruitment hospital [5]
0
0
Novartis Investigative Site - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [2]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [3]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [4]
0
0
3002 - East Melbourne
Query!
Recruitment postcode(s) [5]
0
0
3000 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Connecticut
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Georgia
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Illinois
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Indiana
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Missouri
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New York
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
North Carolina
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Washington
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Wisconsin
Query!
Country [10]
0
0
Argentina
Query!
State/province [10]
0
0
Ciudad Autonoma de Buenos Aires
Query!
Country [11]
0
0
Argentina
Query!
State/province [11]
0
0
Santa Fe
Query!
Country [12]
0
0
Austria
Query!
State/province [12]
0
0
Graz
Query!
Country [13]
0
0
Austria
Query!
State/province [13]
0
0
Innsbruck
Query!
Country [14]
0
0
Austria
Query!
State/province [14]
0
0
Linz
Query!
Country [15]
0
0
Austria
Query!
State/province [15]
0
0
Rankweil
Query!
Country [16]
0
0
Austria
Query!
State/province [16]
0
0
Salzburg
Query!
Country [17]
0
0
Austria
Query!
State/province [17]
0
0
Steyr
Query!
Country [18]
0
0
Austria
Query!
State/province [18]
0
0
Vienna
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Brasschaat
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Brugge
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Leuven
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Lodelinsart
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Turnhout
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
Minas Gerais
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
Paraná
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
Rio Grande Do Sul
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Santa Catarina
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
São Paulo
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
Rio de Janeiro
Query!
Country [30]
0
0
Brazil
Query!
State/province [30]
0
0
Sao Paulo - SP
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
Ontario
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Quebec
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Québec
Query!
Country [34]
0
0
Czechia
Query!
State/province [34]
0
0
Brno
Query!
Country [35]
0
0
Czechia
Query!
State/province [35]
0
0
Ostrava
Query!
Country [36]
0
0
Czechia
Query!
State/province [36]
0
0
Praha 10
Query!
Country [37]
0
0
Czechia
Query!
State/province [37]
0
0
Praha 2
Query!
Country [38]
0
0
Czechia
Query!
State/province [38]
0
0
Praha
Query!
Country [39]
0
0
Denmark
Query!
State/province [39]
0
0
Aarhus
Query!
Country [40]
0
0
Denmark
Query!
State/province [40]
0
0
Koebenhavn Oe
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Angers Cedex 9
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Caen Cedex 9
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Le Mans
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Paris Cedex 12
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Paris
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Pringy Cedex
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Baden-Wuerttemberg
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Bayern
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Niedersachsen
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Nordrhein-Westfalen
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Sachsen
Query!
Country [52]
0
0
Greece
Query!
State/province [52]
0
0
Athens,
Query!
Country [53]
0
0
Greece
Query!
State/province [53]
0
0
Larisa
Query!
Country [54]
0
0
Greece
Query!
State/province [54]
0
0
Patra
Query!
Country [55]
0
0
Greece
Query!
State/province [55]
0
0
Thessaloniki
Query!
Country [56]
0
0
Hong Kong
Query!
State/province [56]
0
0
Chai Wan
Query!
Country [57]
0
0
Hong Kong
Query!
State/province [57]
0
0
Hong Kong
Query!
Country [58]
0
0
Hong Kong
Query!
State/province [58]
0
0
Shatin, New Territories
Query!
Country [59]
0
0
Hong Kong
Query!
State/province [59]
0
0
Tuen Mun
Query!
Country [60]
0
0
Hungary
Query!
State/province [60]
0
0
Debrecen
Query!
Country [61]
0
0
Hungary
Query!
State/province [61]
0
0
Szeged
Query!
Country [62]
0
0
Ireland
Query!
State/province [62]
0
0
Dublin
Query!
Country [63]
0
0
Ireland
Query!
State/province [63]
0
0
Galway
Query!
Country [64]
0
0
Ireland
Query!
State/province [64]
0
0
James Street
Query!
Country [65]
0
0
Ireland
Query!
State/province [65]
0
0
Limerick
Query!
Country [66]
0
0
Ireland
Query!
State/province [66]
0
0
Tallaght, Dublin
Query!
Country [67]
0
0
Israel
Query!
State/province [67]
0
0
Haifa
Query!
Country [68]
0
0
Israel
Query!
State/province [68]
0
0
Holon
Query!
Country [69]
0
0
Israel
Query!
State/province [69]
0
0
Jerusalem
Query!
Country [70]
0
0
Israel
Query!
State/province [70]
0
0
Kfar Saba
Query!
Country [71]
0
0
Israel
Query!
State/province [71]
0
0
Petach-Tikva
Query!
Country [72]
0
0
Israel
Query!
State/province [72]
0
0
Tel Aviv
Query!
Country [73]
0
0
Italy
Query!
State/province [73]
0
0
Calabria
Query!
Country [74]
0
0
Italy
Query!
State/province [74]
0
0
Emilia-Romagna
Query!
Country [75]
0
0
Italy
Query!
State/province [75]
0
0
Liguria
Query!
Country [76]
0
0
Italy
Query!
State/province [76]
0
0
Piemonte
Query!
Country [77]
0
0
Italy
Query!
State/province [77]
0
0
Toscana
Query!
Country [78]
0
0
Korea, Republic of
Query!
State/province [78]
0
0
Seoul
Query!
Country [79]
0
0
Mexico
Query!
State/province [79]
0
0
Nuevo León
Query!
Country [80]
0
0
Mexico
Query!
State/province [80]
0
0
Oaxaca
Query!
Country [81]
0
0
Norway
Query!
State/province [81]
0
0
Bergen
Query!
Country [82]
0
0
Norway
Query!
State/province [82]
0
0
Oslo
Query!
Country [83]
0
0
Peru
Query!
State/province [83]
0
0
Lima
Query!
Country [84]
0
0
Poland
Query!
State/province [84]
0
0
Krakow
Query!
Country [85]
0
0
Poland
Query!
State/province [85]
0
0
Legnica
Query!
Country [86]
0
0
Poland
Query!
State/province [86]
0
0
Lublin
Query!
Country [87]
0
0
Poland
Query!
State/province [87]
0
0
Opole
Query!
Country [88]
0
0
Poland
Query!
State/province [88]
0
0
Slupsk
Query!
Country [89]
0
0
Poland
Query!
State/province [89]
0
0
Torun
Query!
Country [90]
0
0
Puerto Rico
Query!
State/province [90]
0
0
San Juan
Query!
Country [91]
0
0
Russian Federation
Query!
State/province [91]
0
0
Kaluga
Query!
Country [92]
0
0
Russian Federation
Query!
State/province [92]
0
0
Moscow
Query!
Country [93]
0
0
Russian Federation
Query!
State/province [93]
0
0
Penza
Query!
Country [94]
0
0
Russian Federation
Query!
State/province [94]
0
0
St Petersburg
Query!
Country [95]
0
0
Russian Federation
Query!
State/province [95]
0
0
St'Petersburg
Query!
Country [96]
0
0
Spain
Query!
State/province [96]
0
0
Asturias
Query!
Country [97]
0
0
Spain
Query!
State/province [97]
0
0
Barcelona
Query!
Country [98]
0
0
Spain
Query!
State/province [98]
0
0
Gerona
Query!
Country [99]
0
0
Spain
Query!
State/province [99]
0
0
La Laguna (Santa Cruz De Tenerife)
Query!
Country [100]
0
0
Spain
Query!
State/province [100]
0
0
Leon
Query!
Country [101]
0
0
Spain
Query!
State/province [101]
0
0
León
Query!
Country [102]
0
0
Spain
Query!
State/province [102]
0
0
Madrid
Query!
Country [103]
0
0
Spain
Query!
State/province [103]
0
0
Majadahonda (Madrid)
Query!
Country [104]
0
0
Spain
Query!
State/province [104]
0
0
Malaga
Query!
Country [105]
0
0
Spain
Query!
State/province [105]
0
0
Málaga
Query!
Country [106]
0
0
Spain
Query!
State/province [106]
0
0
Oviedo
Query!
Country [107]
0
0
Spain
Query!
State/province [107]
0
0
Palma de Mallorca
Query!
Country [108]
0
0
Spain
Query!
State/province [108]
0
0
Pozuelo De Alarcon/Madrid
Query!
Country [109]
0
0
Spain
Query!
State/province [109]
0
0
Pozuelo De Alarcón/Madrid
Query!
Country [110]
0
0
Spain
Query!
State/province [110]
0
0
Salamanca
Query!
Country [111]
0
0
Spain
Query!
State/province [111]
0
0
Valencia
Query!
Country [112]
0
0
Sweden
Query!
State/province [112]
0
0
Goteborg
Query!
Country [113]
0
0
Sweden
Query!
State/province [113]
0
0
Göteborg
Query!
Country [114]
0
0
Sweden
Query!
State/province [114]
0
0
Stockholm
Query!
Country [115]
0
0
Sweden
Query!
State/province [115]
0
0
Uppsala
Query!
Country [116]
0
0
Switzerland
Query!
State/province [116]
0
0
Aarau
Query!
Country [117]
0
0
Switzerland
Query!
State/province [117]
0
0
Bellinzona
Query!
Country [118]
0
0
Switzerland
Query!
State/province [118]
0
0
Bern
Query!
Country [119]
0
0
Switzerland
Query!
State/province [119]
0
0
Zuerich
Query!
Country [120]
0
0
Taiwan
Query!
State/province [120]
0
0
Changhua
Query!
Country [121]
0
0
Taiwan
Query!
State/province [121]
0
0
Kaohsiung
Query!
Country [122]
0
0
Taiwan
Query!
State/province [122]
0
0
Taipei
Query!
Country [123]
0
0
Thailand
Query!
State/province [123]
0
0
Bangkok
Query!
Country [124]
0
0
Thailand
Query!
State/province [124]
0
0
ChiangMai
Query!
Country [125]
0
0
Turkey
Query!
State/province [125]
0
0
Ankara
Query!
Country [126]
0
0
Turkey
Query!
State/province [126]
0
0
Izmir
Query!
Country [127]
0
0
Turkey
Query!
State/province [127]
0
0
Samsun
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Eltrombopag olamine (SB-497115-GR) is an orally bioavailable, small molecule thrombopoietin receptor agonist that may be beneficial in medical disorders associated with thrombocytopenia. Eltrombopag has been shown to increase platelet counts in patients with thrombocytopenia from various etiologies (Idiopathic thrombocytopenic purpura \[ITP\], liver disease, aplastic anemia and chemotherapy induced thrombocytopenia). Approximately 350 subjects will be randomized in a 1:1 ratio (175 into the eltrombopag arm and 175 into the placebo arm). Approximately 55 subjects will be enrolled into the azacitidine. Subjects with intermediate-1, intermediate-2 or high risk MDS by IPSS, and baseline platelet count of \<75 Giga (10\^9) per liter (Gi/L) will only be enrolled. This is a randomized, double-blind, parallel group, placebo-controlled study designed to explore the platelet supportive care effects of eltrombopag versus placebo in combination with the standard of care hypomethylating agent, azacitidine. The primary objective of this study is to determine the effect of eltrombopag versus placebo on the proportion of subjects who are platelet transfusion free during the first 4 cycles of azacitidine therapy. Key secondary endpoints include overall survival, disease response, and disease progression.
Query!
Trial website
https://clinicaltrials.gov/study/NCT02158936
Query!
Trial related presentations / publications
Dickinson M, Cherif H, Fenaux P, Mittelman M, Verma A, Portella MSO, Burgess P, Ramos PM, Choi J, Platzbecker U; SUPPORT study investigators. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 2018 Dec 20;132(25):2629-2638. doi: 10.1182/blood-2018-06-855221. Epub 2018 Oct 10.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT02158936
Download to PDF